European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C

3 June 2016
156 Views

Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.

The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.

You may be interested

EU Poll: Greeks overwhelmingly convinced of widespread corruption
FINANCE
shares2 views
FINANCE
shares2 views

EU Poll: Greeks overwhelmingly convinced of widespread corruption

makis - Dec 12, 2017

Corruption in Greece is an ongoing political issue, that has been debated to death over the past 35 years. Now…

Turkish PM Yildirim escalates rhetoric against Greece
GREECE
shares10 views
GREECE
shares10 views

Turkish PM Yildirim escalates rhetoric against Greece

makis - Dec 12, 2017

Two days before his arrival in Greece, Turkish PM Binali Yildirim directly disputed the current Status Quo in the Aegean…

One in three Greeks unable to afford basic material goods
GREECE
shares32 views
GREECE
shares32 views

One in three Greeks unable to afford basic material goods

makis - Dec 12, 2017

One in three Greeks or 32% in 2016 were unable to enjoy basic material goods and social benefits, according to…

Leave a Comment

Your email address will not be published.